Spyre tumbles as immune drug misses mark in rheumatoid arthritis

Data ReadoutnegativeNegative

AI Analysis

Summary

Spyre's immune drug targeting TL1A protein failed to meet efficacy endpoints in rheumatoid arthritis, resulting in over $1 billion in market value loss and raising questions about the therapeutic potential of this drug class.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

immune drug blocking TL1A protein missed primary endpoint in rheumatoid arthritis

Importance:7/10

Sentiment:

-0.90

clinical trial failuremarket value lossrheumatoid arthritisTL1A inhibitor

Related Companies

$DMIIR

Read the original article

Published by BioPharma Dive on August 26, 2026 4:25 PM

Read Original